UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)																	
1. Name and Address of Reporting Person * ALCORN HARRY W JR					2. Issuer Name and Ticker or Trading Symbol DiaMedica Therapeutics Inc. [DMAC]							5.	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)Director10% Owner						
(Last) (First) (Middle) TWO CARLSON PARKWAY, SUITE 260					3. Date of Earliest Transaction (Month/Day/Year) 09/15/2021								X Officer (give title below) Other (specify below) SVP, Clinical Operations						
(Street)				4. If	4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person							
	APOLIS, N	1N 55447 (State)	(Zip)																
												uired, Disposed of, or Beneficially Owned							
(Instr. 3) Date			2. Transaction Date (Month/Day/Year)	Execu		Code (Instr. 8)		(A) or Disposed of (D) (Instr. 3, 4 and 5)			D) Beneficially Owned Follow Reported Transaction(s)			Following	Form:		7. Nature of Indirect Beneficial		
				(Month/Day/Year)		Co	de	V	Amount	(A) or (D)	Pri	rice	(Instr. 3 and 4)			Oirector (I) (Instr	direct (I	wnership nstr. 4)	
Voting Common Shares, no par value per share		09/15/2021			P			15,000	A	\$ 3.79	973	43,582			D				
Voting Common Shares, no par value per share												:	399			I	B S	y pouse	
Reminder:	Report on a s	separate line f	or each class of secu	ırities t	peneficially o	wned o	direct	ly or	indirectly	y									
		1						Pers	sons whatained in	o resp	form	are r	not requ		ormation spond unle		SEC 14	74 (9-02)	
			Table II -		ative Securit								Owned						
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day	Execution D	ate, if	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		and Expiration Date (Month/Day/Year) Am Un Sec			ĺ	nt of lying ities 3 and		9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	y D So D On (S) (I	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownershi (Instr. 4)		
				Co	Code V	(A)	(D)	Dat Exe		Expirat Date	tion ,	Title	Amount or Number of Shares						
Repor	ting O	wners																	

	Relationships								
Reporting Owner Name / Address	Director	10% Owner	Officer	Other					
ALCORN HARRY W JR TWO CARLSON PARKWAY SUITE 260 MINNEAPOLIS, MN 55447			SVP, Clinical Operations						

Signatures

/s/Amy Culbert, attorney-in-fact	09/15/2021
-*Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.